An Open-label Study in Healthy Male Subjects to Assess the Effect of Hyperthyroidism Mimicked by Oral Dosing of Levothyroxine on the Pharmacokinetics of Sorafenib

Trial Profile

An Open-label Study in Healthy Male Subjects to Assess the Effect of Hyperthyroidism Mimicked by Oral Dosing of Levothyroxine on the Pharmacokinetics of Sorafenib

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Sorafenib (Primary) ; Levothyroxine sodium
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Gastric cancer; Germ cell and embryonal neoplasms; Glioma; Head and neck cancer; Liver cancer; Myelodysplastic syndromes; Neuroendocrine tumours; Neurofibromatoses; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Soft tissue sarcoma; Thyroid cancer
  • Focus Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 09 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2015 Planned End Date changed from 1 May 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 27 Apr 2015 Planned primary completion date changed from 1 Apr 2015 to 1 May 2015.as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top